Levels of bacterial toxins are decreased in CD patients after receiving anti-TNF mAb (infliximab, IFX) treatment by improving intestinal inflammation, suggesting that the bacterial toxins in sera could help us evaluate the progression of IBD [17]. The gene discussed is TNF; the disease is Cowden disease.